Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.
This site will remain live until Q4 2024 as we transition content to our new site.
American Society for Gene and Cell Therapy 26th Annual Meeting | May 16-20, 2023
International Society for Pharmacoeconomics and Outcomes Research 2023 | May 7-10, 2023
American Academy of Neurology 2023 Annual Meeting | April 22-27, 2023
European Academy of Neurology 8th Annual Congress | June 25 – 28, 2022
American Society of Gene & Cell Therapy Annual Meeting | May 16 – 19, 2022
American Academy of Neurology Annual Meeting | Apr 2 – 7, 2022
Jan Case
investors@swanbiotx.com
Lara Furst
703-946-0183
media@swanbiotx.com